Resource Logo

(BETA) News Briefs: Study of Enhanced Saquinavir Formulation Open to Enrollment


Researchers are actively recruiting for a Phase I/II clinical study of an enhanced, more bioavailable formulation of saquinavir (Invirase), the protease inhibitor drug from Hoffmann-La Roche.

About 90 people are needed at 10 U.S. medical centers for a dose-ranging study comparing 2 formulations of Invirase.

Participants will be randomized to 1 of 4 monotherapy treatment arms for 8 weeks. Afterwards, participants can continue on saquinavir plus the anti-HIV treatment of their choice. Trials are enrolling in Jefferson County, AL; Boston, MA; Jackson County, MO; New York, NY; Portland, OR; and Galvetson, TX. For more information about the study, call Roche at 1-800-526-6367 or 1-800-TRIALS-A.


Copyright © 1995 -BETA, Publisher. All rights reserved to the San Francisco AIDS Foundation. Reproduced by permission. Reproduction of this article (other than one copy for personal reference) must be cleared through BETA: PO Box 426182, San Francisco, CA 94142-6182. Tel: 415 487 8060 Fax: 415 487 8069 San Francisco AIDS Foundation, Mail SFAF..

Information in this article was accurate in September 1, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.